Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

The absolute bioavailability and the effect of food on a new magnesium lactate dihydrate extended-release caplet in healthy subjects.

Dogterom P, Fu C, Legg T, Chiou YJ, Brandon S.

Drug Dev Ind Pharm. 2018 Sep;44(9):1481-1487. doi: 10.1080/03639045.2018.1464020. Epub 2018 Apr 25.

PMID:
29638147
2.

Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation.

Kersemaekers WM, Dogterom P, Xu J, Marcantonio EE, de Greef R, Waskin H, van Iersel ML.

Antimicrob Agents Chemother. 2015;59(6):3385-9. doi: 10.1128/AAC.05000-14. Epub 2015 Mar 30.

3.

The effect of food on the high clearance drug asenapine after sublingual administration to healthy male volunteers.

Dogterom P, de Greef R, Peeters PA.

Eur J Clin Pharmacol. 2015 Jan;71(1):65-74. doi: 10.1007/s00228-013-1587-4. Epub 2015 Jan 1.

PMID:
25552402
4.

Application of absorption modeling to predict bioequivalence outcome of two batches of etoricoxib tablets.

Mitra A, Kesisoglou F, Dogterom P.

AAPS PharmSciTech. 2015 Feb;16(1):76-84. doi: 10.1208/s12249-014-0194-8. Epub 2014 Sep 3.

5.

Asenapine Safety, Tolerability, and Pharmacokinetics After Single and Multiple Doses in Healthy Volunteers.

Dogterom P, Timmer C, de Greef R, Spaans E, de Vries D, van Vliet A, Peeters P.

Clin Pharmacol Drug Dev. 2012 Oct;1(4):131-43. doi: 10.1177/2160763X12455328.

PMID:
27121455
6.

Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial.

Nations KR, Dogterom P, Bursi R, Schipper J, Greenwald S, Zraket D, Gertsik L, Johnstone J, Lee A, Pande Y, Ruigt G, Ereshefsky L.

J Psychopharmacol. 2012 Dec;26(12):1525-39. doi: 10.1177/0269881112458728. Epub 2012 Sep 6.

PMID:
22954616
7.

Maximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection.

Nations KR, Bursi R, Dogterom P, Ereshefsky L, Gertsik L, Mant T, Schipper J.

Drugs R D. 2012 Sep 1;12(3):127-39. doi: 10.2165/11634360-000000000-00000.

8.

Development and validation of automated SPE-HPLC-MS/MS methods for the quantification of asenapine, a new antipsychotic agent, and its two major metabolites in human urine.

de Boer T, Meulman E, Meijering H, Wieling J, Dogterom P, Lass H.

Biomed Chromatogr. 2012 Dec;26(12):1461-3. doi: 10.1002/bmc.2722. Epub 2012 Feb 16.

PMID:
22344545
9.

Asenapine pharmacokinetics in hepatic and renal impairment.

Peeters P, Bockbrader H, Spaans E, Dogterom P, Lasseter K, Marbury T, Gibson GL, de Greef R.

Clin Pharmacokinet. 2011 Jul;50(7):471-81. doi: 10.2165/11590490-000000000-00000.

PMID:
21651314
10.

Translational PK-PD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576.

Bursi R, Erdemli G, Campbell R, Hutmacher MM, Kerbusch T, Spanswick D, Jeggo R, Nations KR, Dogterom P, Schipper J, Shahid M.

Psychopharmacology (Berl). 2011 Dec;218(4):713-24. doi: 10.1007/s00213-011-2365-6. Epub 2011 Jun 7.

PMID:
21647578
11.

Valproate reduces the glucuronidation of asenapine without affecting asenapine plasma concentrations.

Gerrits MG, de Greef R, Dogterom P, Peeters PA.

J Clin Pharmacol. 2012 May;52(5):757-65. doi: 10.1177/0091270011404028. Epub 2011 May 31.

PMID:
21628604
12.
13.
14.

Troglitazone has no effect on red cell mass or other erythropoietic parameters.

Young MM, Squassante L, Wemer J, van Marle SP, Dogterom P, Jonkman JH.

Eur J Clin Pharmacol. 1999 Apr;55(2):101-4.

PMID:
10335903
15.

A study comparing biopharmaceutic characteristics of four once daily controlled release diltiazem preparations.

Hendriks MG, Dogterom P, Ebels JT, Oosterhuis B, Geertsema LR, Hulot T, Bianchetti G, Jonkman JH.

Fundam Clin Pharmacol. 1998;12(5):559-65.

PMID:
9794155
16.

Effect of Felbamate on The Pharmacokinetics of Clonazepam.

Colucci R, Glue P, Banfield C, Reidenberg P, Meehan J, Radwanski E, Korduba C, Lin C, Dogterom P, Ebels T, Hendriks G, Jonkman J, Affrime M.

Am J Ther. 1996 Apr;3(4):294-297.

PMID:
11862264
18.
20.

Cardiotoxicity of vasodilators and positive inotropic/vasodilating drugs in dogs: an overview.

Dogterom P, Zbinden G, Reznik GK.

Crit Rev Toxicol. 1992;22(3-4):203-41. Review.

PMID:
1388706
21.

Role of microtubuli in secretion of very-low-density lipoprotein in isolated rat hepatocytes: early effects of thiol reagents.

Nagelkerke JF, van de Water B, Twiss IM, Zoetewey JP, de Bont HJ, Dogterom P, Mulder GJ.

Hepatology. 1991 Dec;14(6):1259-68.

PMID:
1959877
22.

Lipid peroxidation and protein thiol depletion are not involved in the cytotoxicity of N-hydroxy-2-acetylaminofluorene in isolated rat hepatocytes.

Kroese ED, Bannenberg G, Dogterom P, Noach AB, Nagelkerke JF, Meerman JH.

Biochem Pharmacol. 1990 Oct 15;40(8):1885-92.

PMID:
2242021
25.
26.

Hepatotoxicity of tetrahydroaminoacridine in isolated rat hepatocytes: effect of glutathione and vitamin E.

Dogterom P, Nagelkerke JF, Mulder GJ.

Biochem Pharmacol. 1988 Jun 15;37(12):2311-3. No abstract available.

PMID:
3390201
28.

Supplemental Content

Loading ...
Support Center